All In Biotech

Drug Trial Radar · NCT04097821

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

45

Actual

Start

Sep 26, 2019

Primary completion

May 3, 2023

Study completion Aug 28, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to investigate the safety, pharmacokinetics and preliminary efficacy of combination treatment of ruxolitinib with 5 novel compounds: siremadlin, crizanlizumab, sabatolimab, rineterkib and NIS793 in myelofibrosis (MF) subjects.

Conditions

  • Myelofibrosis

Interventions

  • RuxolitinibDrug

    5 mg tablets for oral use

  • SiremadlinDrug

    10 mg, 20 mg, or 40 mg capsules for oral use

  • CrizanlizumabDrug

    100 mg/10 mL concentrate for infusion for intravenous use

  • SabatolimabDrug

    100 mg/mL or 400 mg/4 mL concentrate for infusion for intravenous use

  • RineterkibDrug

    100 mg capsule for oral use

  • NIS793Drug

    700 mg/7 mL concentrate for infusion for intravenous use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Dose Limiting Toxicities Within the First 2 Cycles in Part 1Time frame: Baseline to the end of Cycle 2 (6 or 8 weeks)
  2. Response Rate at the End of Cycle 6 or Cycle 8 in Part 1Time frame: Baseline to the end of Cycle 6 or 8 (24 weeks)

Locations

22 sites in 13 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Adelaide, South Australia, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Copenhagen, Denmark

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Greifswald, Germany

  • Novartis Investigative Site

    Jena, Germany

  • Novartis Investigative Site

    Mannheim, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Florence, FI, Italy

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Moscow, Russia

  • Novartis Investigative Site

    Alicante, Spain

  • Novartis Investigative Site

    Las Palmas de Gran Canaria, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Salamanca, Castille and León, Spain

  • Novartis Investigative Site

    Stockholm, Sweden

  • Novartis Investigative Site

    Sankt Gallen, Switzerland

  • Novartis Investigative Site

    Zurich, Switzerland

  • Novartis Investigative Site

    Kocaeli, Turkey (Türkiye)

  • Novartis Investigative Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.